JPM-OEt is a broad spectrum (a wide range) inhibitor of cysteine cathepsin. JPM-OEt covalently binds at the active site and irreversibly inhibits the cysteine cathepsin family. Has anti-tumor activity.

Physicochemical Properties

Molecular Formula	C20H28N2O6
Molecular Weight	392.4461
Exact Mass	392.195
CAS #	262381-84-0
PubChem CID	11257859
Appearance	White to off-white solid powder
LogP	1.694
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	11
Heavy Atom Count	28
Complexity	545
Defined Atom Stereocenter Count	3
SMILES	CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC2=CC=C(C=C2)O
InChi Key	VRFYYTLIPKHELT-ULQDDVLXSA-N
InChi Code	InChI=1S/C20H28N2O6/c1-4-27-20(26)17-16(28-17)19(25)22-15(11-12(2)3)18(24)21-10-9-13-5-7-14(23)8-6-13/h5-8,12,15-17,23H,4,9-11H2,1-3H3,(H,21,24)(H,22,25)/t15-,16-,17-/m0/s1
Chemical Name	ethyl (2S,3S)-3-(((S)-1-((4-hydroxyphenethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamoyl)oxirane-2-carboxylate
Synonyms	JPM-OEt JPM OEt JPMOEt JPM-565 Ethyl ester
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	JPM-OEt (50 mg/kg; intraperitoneal injection; once daily for 30 days) effectively lowers tumor cathepsin B activity [1]. JPM-OEt (50 mg/kg; i.p.; twice daily for 4 weeks) causes tumor regression in the RIP1-Tag2 (RT2) animal model of islet cell carcinogenesis [2]. JPM-OEt (50 mg/kg; i.p.; daily for 63 to 98 days) produces a considerable delay in the growth in tumor burden within the first 2 weeks of treatment [3].
Animal Protocol	Animal/Disease Models: Transgenic mice Female mice [3] Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day from 63 to 98 days Experimental Results: The increase in tumor burden was Dramatically delayed during the first 2 weeks of treatment. However, no significant differences were detected between the two groups on days 84, 91, and 98.
References	[1]. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199-209. [2]. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug 1;67(15):7378-85. [3]. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem. 2008 Aug;389(8):1067-74.

Solubility Data

Solubility (In Vitro)

DMSO : ~125 mg/mL (~318.51 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 6.25 mg/mL (15.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (15.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 6.25 mg/mL (15.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.5481 mL	12.7405 mL	25.4810 mL
	5 mM	0.5096 mL	2.5481 mL	5.0962 mL
	10 mM	0.2548 mL	1.2740 mL	2.5481 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.